Last reviewed · How we verify

NCT01764230: OVARONKO

Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients

Completed NA Last updated 7 January 2013
What this trial tests

NA trial testing triptorelin in Hodgkin Lymphoma in 72 participants. Completed in 1 January 2008.

Timeline
1 January 2004
Primary endpoint
1 July 2007
1 January 2008

Quick facts

Lead sponsorMasaryk University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment72
Start date1 January 2004
Primary completion1 July 2007
Estimated completion1 January 2008
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Masaryk University

Who can join

Adults 18 to 35, female only, with Hodgkin Lymphoma or Hodgkin Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Chemotherapy as one of the basic modalities of oncology treatment often leaves permanent implications and among the most common is infertility as a result of irreversible gonadal damage. This project sets the primary target to verify the protective effect GnRH analogues administration to protect ovarian tissue during three different regimens of chemotherapy in patients with Hodgkin disease (HD) in reproductive age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of triptorelin

Trials testing the same drug.

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

Other Masaryk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01764230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing